Brief: Iovance Announces Five-Year Results Of Amtagvi® (Lifileucel) In Patients With Advanced Melanoma At Asco Annual Meeting
22/05/2025 22:32
Iovance Biotherapeutics Inc IOVA.O: IOVANCE ANNOUNCES FIVE-YEAR RESULTS OF AMTAGVI® (LIFILEUCEL) IN PATIENTS WITH ADVANCED MELANOMA AT ASCO ANNUAL MEETING IOVANCE BIOTHERAPEUTICS INC: ONE-TIME AMTAGVI TREATMENT DEMONSTRATED DURABLE RESPONSES AND A FIVE-YEAR OVERALL SURVIVAL RATE OF 20% Source text: ID:nGNX9mBFn3 Further company coverage: IOVA.O
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies